Arvinas (ARVN) announced that John Houston, Chairperson, CEO, and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, and the appointment of, the Company’s new CEO. The Arvinas Board of Directors has begun a search for a new CEO, and Dr. Houston will remain Chairperson of Arvinas’ Board of Directors upon retiring as President and CEO. With more than 35 years of experience in the pharmaceutical and biotech industries, Houston joined Arvinas in January 2017 as President of Research and Development and Chief Scientific Officer responsible for leading the discovery, translational, and early clinical development research efforts. In September 2017, Houston was appointed President and CEO, and in 2023 he was named Arvinas’ Chairperson.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN: